Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $33.00.

A number of equities analysts have recently issued reports on AVTX shares. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, January 15th. Guggenheim initiated coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th.

Avalo Therapeutics Stock Performance

NASDAQ AVTX opened at $16.02 on Tuesday. Avalo Therapeutics has a one year low of $3.39 and a one year high of $20.72. The company has a market capitalization of $296.53 million, a price-to-earnings ratio of -2.99 and a beta of 0.84. The company’s 50-day simple moving average is $15.89 and its two-hundred day simple moving average is $15.61.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new position in Avalo Therapeutics in the fourth quarter valued at about $1,150,000. XTX Topco Ltd lifted its position in shares of Avalo Therapeutics by 190.0% during the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after buying an additional 26,508 shares during the last quarter. Squadron Capital Management LLC bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $2,361,000. SummitTX Capital L.P. bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $3,557,000. Finally, Millennium Management LLC grew its position in shares of Avalo Therapeutics by 380.2% in the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after buying an additional 522,548 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.